IPO Trending
CHEMCONEQ / NSE, BSEListed

Chemcon Speciality Chemicals Limited

Chemcon Speciality Chemicals Ltd, incorporated in 1988, is engaged in the manufacturing of specialised chemicals such as HMDS and CMIC, along with oilfield chemicals including calcium bromide, sodium bromide, and zinc bromide, pharma intermediates, silanes, and contract manufacturing services. Pharmaceutical chemicals form the largest part of its revenue, with key customers comprising Hetero Labs, Laurus Labs, Aurobindo Pharma, Lantech Pharmaceuticals, and Macleods Pharma, while in the oilfield chemicals segment it caters to clients like Shree Radha Overseas, Universal Drilling Fluids, and Water Systems Speciality. In 2018, the company ranked as the eighth-largest HMDS manufacturer and the second-largest CMIC manufacturer globally, highlighting its strong market position. Chemcon serves both domestic and international markets, exporting to countries such as the USA, China, Japan, UAE, Serbia, Russia, Malaysia, and Azerbaijan, and operates its manufacturing facility at Manjusar near Vadodara, Gujarat, which includes five production plants, three owned warehouses, and two leased warehouses.

₹338 - ₹340149.3x sub
Listed Price731.00
Listing Gain+115.00%
Review-Analyst Consensus Verdict

May apply

No review summary is available yet.

Apply
00%
May Apply
00%
Neutral
00%
Avoid
00%
Not Rated
00%
No IPO review records are available for this issue yet.